Objective: Most of the cur.rent treatments for osteoarthritis are palliative and attack the symptoms rather than influencing the biochemical environment of the joint. Autologous Platelet-rich plasma (PRP), containing growth factors and anti-inflammatory cytokines are considered the future direction of treatment effects on the environment-biological molecules for arthritis osteoarthritis. Methods: In this observational retrospective cohort randomized study, the authors used acid hyalorunic (Hyalgan) injection as a control. In each group included 15 patients with primary knee osteoarthritis in 2 or 3 Kellgren and Lawrence x-ray stages, matched according to age, sex, BMI and x-ray stage. Patients who met the study criteria received three 6ml PRP (ACP technique of Arthrex Inc, USA) or 2ml Hyalgan injections in the affected knee at l-wk intervals. Clinical outcome measures included VAS, WOMAC scale prior to treatment and at 1-week, 2-week and 1, 2 month follow-up visits. Results: Two months after treament, the average score of VAS decreased from 6.9 to 3.6 and overall WOMAC from 46.3 to 20.6 points; the observed success rates in pain subscale of WOMAC for the PRP group was 55.6 percent and better than the Hyalgan group, 42.1 percent. Slightly increased pain rates after injection was 11.1 percent (2/18 joints); joint efusion rates was 5.6 percent (1/18 joints). Conclusions: The first step shows the effect and safety of PRP therapy in the treatment of knee osteoarthritis; need further study with longer duration, larger patients in each group to evaluate the effectiveness of the PRP treatment on cartilage thickness.
- Đăng nhập để gửi ý kiến